Learning Objectives This CME activity has been planned for dermatologists. Upon completion of this program, participants will be able to: 1. Assess the risks and benefits of using topical immunomodulators. 2. Understand where topical immunomodulators fit within the scope of current treatments for atopic dermatitis. 3. Determine where on the body topical immunomodulators are most effective. Accreditation and Educational Credit The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. The University of Michigan Medical School designates this educational activity for a maximum of 1.0 hour of category 1 credit towards the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity. Disclosure Statements The Accreditation Council for Continuing Medical Education and the Association of American Colleges have standards and guidelines to ensure that individuals participating in CME activities are aware of relationships between authors and commercial companies that could potentially affect the information presented. The University of Michigan Medical School follows these national policies to ensure balance, independence, objectivity, and scientific rigor in all its CME programs. Each author was asked to complete a disclosure information form for this activity. Disclosures are described below: Sakari Reitamo, MD: Receives grant support from Fujisawa, Novartis, and Leo; Consultant and speaker for Fujisawa. Anne W. Lucky, MD: Receives grant support from Fujisawa and Novartis; Consultant for Novartis. Amy S. Paller, MD: Consultant and speaker for Fujisawa and Novartis. Charles N. Ellis, MD: Consultant and investigator for Fujisawa and Novartis.